Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.